CATALYST PHARMACEUTICALS INC. - COMMON STOCK

Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies

08 Mar 2023 11:20:58 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023

01 Mar 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Ring the Nasdaq Closing Bell in Honor of International Rare Disease Day

22 Feb 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance

07 Feb 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII

25 Jan 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra

23 Jan 2023 13:25:09 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®

23 Jan 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd

19 Dec 2022 16:10:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update

09 Nov 2022 16:11:31 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year

07 Nov 2022 08:03:37 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022

25 Oct 2022 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for FIRDAPSE® Expanding Patient Population to Include Pediatric Patients

29 Sep 2022 11:18:17 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

09 Sep 2022 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals To Participate in Citi's 17th Annual BioPharma Conference

24 Aug 2022 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Delivers Strong Second Quarter 2022 Financial Results with Record FIRDAPSE® Revenues and Provides Corporate Update

09 Aug 2022 16:26:30 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022

26 Jul 2022 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Settlement of U.S. Patent Litigation and Resolution of Litigation Challenging Ruzurgi® Approval with Jacobus Pharmaceutical

12 Jul 2022 06:00:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

17 May 2022 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update

10 May 2022 16:11:56 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022

25 Apr 2022 08:03:00 By Nasdaq GlobeNewswire